Latest Conference Articles

Sarilumab shows promise on circulating biomarkers of bone and joint destruction in patients with rheumatoid arthritis who had shown an inadequate response to methotrexate.

Patients with rheumatoid arthritis who demonstrate a less-than-adequate response to a tumor necrosis factor inhibitor can be treated with another disease-modifying antirheumatic drug.

Regulatory perspectives presented at ACR on biosimilars entering the market convey the importance of crafting antibodies to our own purposes.

New guidelines for rheumatoid arthritis treatment discussed at ACR conference.

ACR session reinforces the need for new research about how the genome, epigenome, and other factors play a role in rheumatoid arthritis.

There is building consensus that multiple sclerosis and rheumatoid arthritis display similar autoimmune genetic pathways.

Clinicians who marry technical skills with humanities can see their patients and themselves in the larger context of family, society, history, politics, and economics.

Using data and bioinformatics could hold the key to numerous treatment options.

Anti-tumor necrotic factor drugs could help delay hip deterioration in patients with ankylosing spondylitis.

Telehealth broadly is about creating care connections across boundaries, care that encourages patients’ independence, prevention and wellness; and care that can be leveraged for needed interventions. If we get telehealth right we can reduce impact of what we know is a growing health workforce shortage and concurrently create a healthier, more engaged patient base.

The 12-biomarker test is gaining acceptance among rheumatologists and was recently added to a clinical guideline.

Be careful what you wish for: SGR and FFS will be models of the past; the success of the APM and MIPS will rely on compensation, collaboration and participation; and, to date, much remains to be done in the development of quality-based payment reform under MACRA.

New therapeutic targets provide hope for targeted treatments for rheumatoid diseases.

JAK inhibitors may be more effective than older biologic drugs in certain patients.

New data from studies of multiple drugs highlights Janssen’s commitment to rheumatic diseases.

Pfizer will highlight successes of Xeljanz at ACR/ARHP annual meeting.

Amgen will present findings from clinical studies of both branded and investigational drugs.

Positive data from a pair of clinical trials announced at the 25th European Academy of Dermatology and Venereology Congress show Dupixent (dupilumab) is an effective option for moderate-to-severe atopic dermatitis.

Research presented at the 25th European Academy of Dermatology and Venereology Congress focused on the effects of crisaborole topical ointment in treating atopic dermatitis.

Results from clinical trials of Taltz presented at the European Academy of Dermatology and Venereology Congress.

New data for dupilumab presented at the 25th European Academy of Dermatology and Venereology Congress.

At the 25th European Academy of Dermatology and Venereology Congress in Vienna, Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health, discussed effective techniques to boost HIV drug adherence.

The promise of sentinel lymph node biopsies for melanoma highlighted at the 25th European Academy of Dermatology and Venereology Congress in Vienna, Austria.

Immune checkpoint inhibitors could improve malignant melanoma therapy, according to a study presented at the Congress of the European Academy of Dermatology and Venerology.

At the 25th European Academy of Dermatology and Venereology Congress in Vienna, Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health, discussed the importance of persistence in Truvada use for HIV pre-exposure prophylaxis.

AbbVie’s experimental compound treats moderate-to-severe chronic plaque psoriasis.

At the 25th European Academy of Dermatology and Venereology Congress in Vienna, Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health, discussed hurdles to proper drug adherence in HIV treatment.

Clinical trial presented at the 25th Annual European Academy of Dermatology and Venereology Congress found a new topical allantoin cream can help treat epidermolysis bullosa.